Ticker
ALDX

Price
5.20
Stock movement down
-0.26 (-4.76%)
Company name
Aldeyra The
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
303.17M
Ent verdi
176.26M
Pris/omsetning
-
Pris/bok
1.59
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-32.29%
3 års avkastning
-9.90%
5 års avkastning
-4.07%
10 års avkastning
-
Sist oppdatert: 2022-11-29

UTBYTTE

ALDX betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok1.59
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall58.30M
EPS (TTM)-991.09
FCF per aksje (TTM)-729.92

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-61.87M
Netto inntekt (TTM)-57.78B
EPS (TTM)-991.09
EPS (1 år fremover)-1.43

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter158.91M
Netto fordringer65.00M
Samlede omløpsmidler222.36M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler222.69M
Leverandørgjeld2.44M
Kortsiktig/nåværende langsiktig gjeld15.89M
Sum kortsiktig gjeld16.35M
Sum gjeld32.00M
Aksjonærenes egenkapital190.69M
Netto varige driftsmidler190.69M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-42.56B
Kapitalutgifter (TTM)16.32K
Fri kontantstrøm (TTM)-42.56B
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-30301.62%
Avkastning på eiendeler-25946.83%
Avkastning på investert kapital-28011.98%
Kontantavkastning på investert kapital-20630.36%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning5.39
Daglig høy5.61
Daglig lav5.16
Daglig volum202K
Tidenes høyeste14.85
1 år analytikerestimat20.13
Beta1.36
EPS (TTM)-991.09
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
ALDXS&P500
Nåværende prisfall fra toppnotering-64.98%-17.12%
Høyeste prisfall-88.71%-56.47%
Dato for høyeste fall16 Mar 20209 Mar 2009
Gj.snittlig fall fra topp-46.36%-11.46%
Gj.snittlig tid til ny topp120 days13 days
Maks tid til ny topp919 days1805 days
SELSKAPSOPPLYSNINGER
ALDX (Aldeyra The) company logo
Markedsverdi
303.17M
Markedsverdi kategori
Small-cap
Beskrivelse
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Ansatte
14
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Todd C. Brady
Land
USA
By
Lexington
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
LEXINGTON, Mass., November 29, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) f...
29. november 2022
LEXINGTON, Mass., November 10, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated disea...
10. november 2022
LEXINGTON, Mass., November 03, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, November 10, 2022 to report financial results for the qua...
3. november 2022
Aldeyra Therapeutics Inc. develops innovative therapies designed to treat immune-mediated diseases. In this daily bar chart of ALDX, below, we can see that ALDX had a rocky path to a low in May. Pri...
2. november 2022
LEXINGTON, Mass., October 26, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chambe...
26. oktober 2022
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoint in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, USP) for intravitreal administration to prevent prolifer...
6. oktober 2022
LEXINGTON, Mass., October 06, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company) today announced the achievement of the primary endpoint in Part 1 of the Phase 3 GUARD Trial of A...
6. oktober 2022
LEXINGTON, Mass., October 05, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to re...
5. oktober 2022
LEXINGTON, Mass., September 14, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application)...
14. september 2022
LEXINGTON, Mass., September 07, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated dise...
7. september 2022
Neste side